Can Gut Microbes Influence Alzheimer’s Disease? What the Research Shows

The most common cause of dementia, Alzheimer’s disease (AD), is a devastating neurodegenerative disorder. It has no known cure. Although some medications may delay the loss of cognition and memory, definitive interventions remain elusive.

To that end, recent research has increasingly focused on the role of the human microbiome in regulating neurochemical pathways through the gut–brain axis. This IPA blog describes the links between gut microbiota and AD in addition to the potential of targeted strategies for modifying disease risk and progression.

---

Alzheimer’s disease, in brief

It is estimated that more than 55 million people worldwide live with AD, with projections reaching nearly 139 million by 2050.

AD is a slowly progressive disease characterized by neuropathological changes that begin years before symptoms emerge. Early signs often include difficulty remembering recent events, followed by impaired communication, confusion, behavioral changes, and ultimately loss of physical function.

The most obvious risk factor is age, with the majority of individuals affected being 65 or older. Numerous other risk factors for AD include genetic factors (APOE-e4 and genetic mutations), traumatic brain injury, gender (female), education, lifestyle (poor diet, inactivity, smoking), disease (cancer, cardiac, and metabolic), and environmental factors (chemical exposure).

The hallmark pathologies of AD include extracellular accumulation of beta-amyloid (plaques) and intracellular neurofibrillary tangles composed of tau protein. These changes are accompanied by neuronal loss and brain atrophy.

Diagnosis is primarily clinical, supported by imaging and fluid biomarkers, with confirmation only on autopsy.

Current medications, including cholinesterase inhibitors and memantine, provide modest symptomatic benefit but do not modify the underlying disease course. Much research also focuses on the impact of lifestyle on controlling modifiable risk factors.

Among these actionable targets, the gut microbiome has emerged as a particularly promising focus of AD research.

---

Alzheimer’s disease and the microbiome

The gut microbiota plays a central role in regulating neurochemical pathways through the gut–brain axis—a bidirectional communication system linking the gut and brain. This network operates through multiple interconnected pathways:

• Neural signaling (via the autonomic nervous system)
• Endocrine signaling (hormones)
• Immune pathways (cytokines and chemokines)
• Metabolic signaling (microbial metabolites such as short-chain fatty acids (SCFAs)

Together, these systems form a complex network that connects gut health to brain function, influencing processes such as inflammation, oxidative stress, insulin regulation, and lipid metabolism.

Dysbiosis

Disruptions in this axis have been implicated in neurodegenerative diseases, including AD. However, it remains unclear whether microbiome changes are a cause, a consequence, or part of a bidirectional relationship in disease progression.

Emerging evidence shows that aging, diet, medications, and other lifestyle factors can alter gut microbiota composition—a state known as dysbiosis—which is associated with increased neuroinflammation and neurodegeneration.

Aging itself —the biggest risk factor in AD— alters the gut microbiota and changes may favor increased intestinal permeability, impaired blood-brain barrier function, and the development of a neuroinflammatory cascade. Researchers found that older adults showed an increased abundance of the pro-inflammatory bacteria Escherichia/Shigella, whereas individuals with evidence of amyloid deposition on PET imaging exhibited decreased abundance of the anti-inflammatory bacteria Eubacterium rectale. 

Studies in both rodent models and humans show that the gut microbiota is altered in AD.

Clinical examples

• An analysis of the microbiome between healthy subjects and AD patients among 108 nursing home elders showed a lower prevalence of bacteria synthesizing the anti-inflammatory and neuroprotective SCFA butyrate and higher levels of pro-inflammatory taxa.
• A study on subjects with normal vs. impaired cognition showed no notable difference in microbiome diversity, but several unique microbial signatures were detected in subjects with mild cognitive impairment.
• Another study with AD patients revealed distinct shifts in gut bacterial genera linked to higher levels of lipopolysaccharide (LPS), pro-inflammatory cytokines, and markers of endothelial dysfunction. These changes correlated with amyloid accumulation, tau pathology, and neurodegeneration—associations not seen in non-AD cognitive impairment.

This shift toward a pro-inflammatory, low–SCFA–producing microbiome is a recurring finding in AD, although variability exists across populations.

---

Mechanisms linking the microbiome and Alzheimer’s disease

Dysbiosis may contribute to AD through multiple overlapping pathways:

Neurotransmitter dysregulation

Gut microbes influence the production and regulation of neurotransmitters, including acetylcholine, gamma-aminobutyric acid (GABA), serotonin, brain-derived neurotrophic factor (BDNF), and glutamate. Microbial metabolites can stimulate intestinal endocrine cells to produce neuroactive compounds affecting brain function.  

Neuroinflammation and barrier dysfunction

When dysbiosis weakens gut and blood–brain barriers, inflammatory molecules such as LPS and amyloids can enter circulation and the brain, contributing to neuroinflammation, neuronal damage, and disease progression.

Short-chain fatty acids

SCFAs—particularly butyrate—are now considered central mediators, influencing microglial activation, blood–brain barrier integrity, and gene expression through epigenetic pathways.

Amyloids

Emerging evidence suggests that gut dysbiosis promotes the production of bacterial amyloids, which may cross-seed with host amyloid-β and accelerate protein misfolding and aggregation in the brain.

Oxidative stress

Dysbiosis can drive oxidative stress in AD by increasing pro-oxidant metabolites such as LPS and trimethylamine-N-oxide (TMAO), which stimulate inflammatory and oxidative stress within mitochondria.

HPA axis dysregulation

The gut microbiota influences the stress response via the hypothalamic–pituitary–adrenal axis, which may further affect neurodegeneration.

Metabolic and hormonal signaling

Gut-derived hormones such as ghrelin and leptin influence cognition, energy balance, and neuronal signaling.

---

Modulation of gut microbiota in Alzheimer’s disease

Preclinical and clinical studies suggest that modifying the gut microbiota may produce:

• Anti-inflammatory effects
• Reduced oxidative stress
• Improved metabolic signaling
• Potential improvements in cognitive function

However, these effects are variable and not yet standardized.

Probiotics and Alzheimer’s disease

Probiotics are defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit.”

Lactobacilli and bifidobacteria, which generally have well-established safety profiles, are mainly used in probiotic interventions in AD.

Animals

Animal studies consistently show that probiotics can improve cognition in AD models, likely through strain-specific effects on neuroinflammation, oxidative stress, and synaptic function.

Humans

Although clinical studies remain limited and relatively small, several trials suggest potential benefits in cognition and gut microbiota composition.

• A 12-week trial found that B. breve supplementation improved cognitive function in older adults with memory impairment.
• In patients with AD, a 12-week intervention with a probiotic-enriched milk containing L. acidophilus, L. casei, B. bifidum, and L. fermentum improved learning and memory compared to controls.
• Another study reported that a multispecies probiotic formulation altered gut microbiota composition in AD patients, including increased levels of the anti-inflammatory bacterium Faecalibacterium prausnitzii.

A 2025 umbrella meta-analysis found that beneficial effects of probiotics on cognitive health—including potential benefits for patients with cognitive impairment or AD—are supported by moderate- to high-quality evidence, though further clinical trials are needed to determine optimal strains and dosages.

Prebiotics and Alzheimer’s disease

Prebiotic is described as “a substrate that is selectively utilized by host microorganisms conferring a health benefit.”

Prebiotics such as fructooligosaccharides (FOS) and galactooligosaccharides (GOS) are fermented by the gut microbiota into metabolites (such as SCFAs) that influence immune signaling, neuroinflammation, and gut–brain communication, making them of interest in AD research.

In preclinical models, FOS has been shown to improve cognitive function and reduce amyloid and tau-related pathology while modulating synaptic proteins and gut–brain signaling pathways.

In a high-fat diet mouse model, combined FOS and GOS improved cognition and synaptic plasticity while reducing neuroinflammation, amyloid/tau pathology, and gut dysbiosis, partly through restoration of insulin and gut–brain signaling pathways.

Despite these mechanistic findings, human evidence on prebiotics in AD remains limited and inconclusive.

---

Emerging directions

The microbiome as a biomarker

Gut microbiota–based biomarkers are being explored for early AD detection, with studies identifying altered microbial composition, reduced diversity, and changes in metabolites such as TMAO, SCFAs, and tryptophan derivatives. Some of these changes may precede amyloid deposition, suggesting a potential role in early diagnosis.

Diet as modulator

Diet is a key driver of microbiome-related risk in AD. Western diets disrupt gut microbial balance and promote inflammation and insulin resistance, whereas foods comprising Mediterranean, MIND, and DASH diets, including fruits, leafy green vegetables, fish, nuts, and olive oil, may reduce cognitive decline. For example,  Mediterranean-style patterns enhance beneficial bacteria and metabolites, supporting anti-inflammatory, antioxidant, and neuroprotective pathways. Other dietary regimes, including ketogenic and intermittent fasting, are also being studied for potential benefit in AD.

Furthermore, specific nutrients—particularly combinations of B vitamins and omega-3 fatty acids— appear to benefit individuals with metabolic risk or early cognitive impairment. However, a 2026 longitudinal study challenged this prevailing view with findings that suggested, “omega-3 supplementation may be associated with accelerated cognitive decline in older adults, potentially through adverse effects on cerebral synaptic function rather than classical AD proteinopathies.” Caution is advised.

---

Takeaway

Although research on the microbiome and AD is still evolving, growing evidence suggests that gut microbes may influence neuroinflammation, metabolism, oxidative stress, and other pathways involved in disease progression. Recent studies increasingly characterize AD-related dysbiosis by reduced SCFA–producing bacteria and enrichment of pro-inflammatory taxa, while microbial metabolites such as butyrate are now viewed as important regulators of gut and blood–brain barrier integrity and immune signaling.

Probiotics, prebiotics, and diet therefore represent promising and potentially sustainable strategies for supporting brain health and possibly slowing disease progression. However, current clinical evidence remains limited. Further research is needed to determine the most effective interventions, including optimal strains, dosing, and timing relative to disease progression.

Image by Gerd Altmann from Pixabay

---

Key references

Abdol Samat, Hanis Nabilah et al. “The Interplay of Inflammation and Gut-Microbiota Dysbiosis in Alzheimer’s Disease: Mechanisms and Therapeutic Potential.” International journal of molecular sciences vol. 26,18 8905. 12 Sep. 2025, doi:10.3390/ijms26188905

Agrawal, Ishan, and Sushmita Jha. “Mitochondrial Dysfunction and Alzheimer’s Disease: Role of Microglia.” Frontiers in aging neuroscience vol. 12 252. 20 Aug. 2020, doi:10.3389/fnagi.2020.00252

Akbari, Elmira et al. “Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial.” Frontiers in aging neuroscience vol. 8 256. 10 Nov. 2016, doi:10.3389/fnagi.2016.00256

Alzheimer’s Disease International. “Dementia Statistics.” Alzheimer’s Disease International, 2025.

Armstrong, Richard. “Risk factors for Alzheimer’s disease.” Folia neuropathologica vol. 57,2 (2019): 87-105. doi:10.5114/fn.2019.85929

Arora, Sarah et al. “Diet and lifestyle impact the development and progression of Alzheimer’s dementia.” Frontiers in nutrition vol. 10 1213223. 29 Jun. 2023, doi:10.3389/fnut.2023.1213223

Bonfili, Laura et al. “Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease.” The FEBS journal vol. 288,9 (2021): 2836-2855. doi:10.1111/febs.15571

Bou Zerdan, Maroun et al. “The Gut Microbiome and Alzheimer’s Disease: A Growing Relationship.” Current Alzheimer research vol. 19,12 (2022): 808-818. doi:10.2174/1567205020666221227090125

Breijyeh, Zeinab, and Rafik Karaman. “Comprehensive Review on Alzheimer’s Disease: Causes and Treatment.” Molecules (Basel, Switzerland) vol. 25,24 5789. 8 Dec. 2020, doi:10.3390/molecules25245789

Caldwell, Jessica Z K, and Nancy Isenberg. “The aging brain: risk factors and interventions for long term brain health in women.” Current opinion in obstetrics & gynecology vol. 35,2 (2023): 169-175. doi:10.1097/GCO.0000000000000849

Cattaneo, Annamaria et al. “Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly.” Neurobiology of aging vol. 49 (2017): 60-68. doi:10.1016/j.neurobiolaging.2016.08.019

Charbit, Judith et al. “Effects of Dietary Interventions on Cognitive Outcomes.” Nutrients vol. 17,12 1964. 9 Jun. 2025, doi:10.3390/nu17121964

de Paiva, Igor Henrique Rodrigues et al. “Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Improve Neuroinflammation and Cognition By Up-regulating IRS/PI3K/AKT Signaling Pathway in Diet-induced Obese Mice.” Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology vol. 18,3 (2023): 427-447. doi:10.1007/s11481-023-10069-8

Doroszkiewicz, Julia, and Barbara Mroczko. “New Possibilities in the Therapeutic Approach to Alzheimer’s Disease.” International journal of molecular sciences vol. 23,16 8902. 10 Aug. 2022, doi:10.3390/ijms23168902

Farzi, Aitak et al. “Gut Microbiota and the Neuroendocrine System.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. 15,1 (2018): 5-22. doi:10.1007/s13311-017-0600-5

Fleishman, Clare. “Healthy Aging and the Microbiome.” WholeFoods Magazine, 29 Mar. 2022.

Friedland, Robert P et al. “What Are the Molecular Mechanisms by Which Functional Bacterial Amyloids Influence Amyloid Beta Deposition and Neuroinflammation in Neurodegenerative Disorders?.” International journal of molecular sciences vol. 21,5 1652. 28 Feb. 2020, doi:10.3390/ijms21051652

Goshtasbi, Hamieh et al. “Impacts of oxidants and antioxidants on the emergence and progression of Alzheimer’s disease.” Neurochemistry international vol. 153 (2022): 105268. doi:10.1016/j.neuint.2021.105268

Goyal, Divya et al. “Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer’s disease.” Progress in neuro-psychopharmacology & biological psychiatry vol. 106 (2021): 110112. doi:10.1016/j.pnpbp.2020.110112

Haran, John P et al. “Alzheimer’s Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway.” mBio vol. 10,3 e00632-19. 7 May. 2019, doi:10.1128/mBio.00632-19

Kachoueiyan, Faeze et al. “Butyrate: a key mediator of gut-brain communication in Alzheimer’s disease.” Metabolic brain disease vol. 40,5 189. 23 Apr. 2025, doi:10.1007/s11011-025-01617-7

Kobayashi, Y et al. “Effects of Bifidobacterium breve A1 on the cognitive function of older adults with memory complaints: a randomised, double-blind, placebo-controlled trial.” Beneficial microbes vol. 10,5 (2019): 511-520. doi:10.3920/BM2018.0170

Koga-Batko, Joanna et al. “Influence of the Gut Microbiota on the Pathogenesis of Alzheimer’s Disease: A Literature Review.” Cells vol. 14,20 1578. 11 Oct. 2025, doi:10.3390/cells14201578

Kowalski, Karol, and Agata Mulak. “Brain-Gut-Microbiota Axis in Alzheimer’s Disease.” Journal of neurogastroenterology and motility vol. 25,1 (2019): 48-60. doi:10.5056/jnm18087

Leblhuber, Friedrich et al. “Probiotic Supplementation in Patients with Alzheimer’s Dementia – An Explorative Intervention Study.” Current Alzheimer research vol. 15,12 (2018): 1106-1113. doi:10.2174/1389200219666180813144834

Liao, Zheng-Bin et al. “The association between omega-3 supplementation and cognitive decline in older adults.” The journal of prevention of Alzheimer’s disease vol. 13,6 (2026): 100569. doi:10.1016/j.tjpad.2026.100569

Liu, Ping et al. “Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort.” Brain, behavior, and immunity vol. 80 (2019): 633-643. doi:10.1016/j.bbi.2019.05.008

Liu, Xiaoxia et al. “Probiotics and Cognitive-Related Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Randomized Controlled Trials.” Nutrition reviews vol. 83,11 (2025): 2144-2158. doi:10.1093/nutrit/nuaf156

Marizzoni, Moira et al. “A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers.” Alzheimer’s research & therapy vol. 15,1 101. 31 May. 2023, doi:10.1186/s13195-023-01218-5

Nagpal, Ravinder et al. “Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment.” EBioMedicine vol. 47 (2019): 529-542. doi:10.1016/j.ebiom.2019.08.032

Noach, Sasja et al. “Effects of multidomain lifestyle interventions on cognitive decline and Alzheimer’s disease prevention: A literature review and future recommendations.” Cerebral circulation – cognition and behavior vol. 4 100166. 13 May. 2023, doi:10.1016/j.cccb.2023.100166

Park, Soo-Hyun et al. “Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: a case report.” Current medical research and opinion vol. 37,10 (2021): 1739-1744. doi:10.1080/03007995.2021.1957807

Parker, Aimée et al. “Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health.” Gut microbes vol. 11,2 (2020): 135-157. doi:10.1080/19490976.2019.1638722

Pistollato, Francesca et al. “Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease.” Nutrition reviews vol. 74,10 (2016): 624-34. doi:10.1093/nutrit/nuw023

Queiroz, Sarha A L et al. “The Gut Microbiota-Brain Axis: A New Frontier on Neuropsychiatric Disorders.” Frontiers in psychiatry vol. 13 872594. 1 Jun. 2022, doi:10.3389/fpsyt.2022.872594

Rajan, Kumar B et al. “Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia.” Neurology vol. 85,10 (2015): 898-904. doi:10.1212/WNL.0000000000001774

Ramesh, Adarsh Srinivas et al. “Role of Fecal Microbiota Transplantation in Reducing Clostridioides difficile Infection-Associated Morbidity and Mortality: A Systematic Review.” Cureus vol. 14,8 e28402. 25 Aug. 2022, doi:10.7759/cureus.28402

Savignac, H M et al. “Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice.” Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society vol. 26,11 (2014): 1615-27. doi:10.1111/nmo.12427

Shajahan, Shah Rezlan et al. “Microbiota-Gut-Brain Axis in Alzheimer’s Disease: Linking Oxidative Stress, Mitochondrial Dysfunction and Amyloid Pathology-A Systematic Review.” Biomedicines vol. 14,4 860. 9 Apr. 2026, doi:10.3390/biomedicines14040860

Siddiqui, Ruqaiyyah et al. “The Use of Gut Microbial Modulation Strategies as Interventional Strategies for Ageing.” Microorganisms vol. 10,9 1869. 19 Sep. 2022, doi:10.3390/microorganisms10091869

Sun, Jing et al. “Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota.” Journal of agricultural and food chemistry vol. 67,10 (2019): 3006-3017. doi:10.1021/acs.jafc.8b07313

Sweeney, Melanie D et al. “Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.” Nature reviews. Neurology vol. 14,3 (2018): 133-150. doi:10.1038/nrneurol.2017.188

Tabaza, Raghad, and Richard E Hartman. “Impact of Gut-Brain Axis and Probiotics on Alzheimer’s Disease.” Neurology international vol. 17,10 153. 24 Sep. 2025, doi:10.3390/neurolint17100153

Waite, Louise M. “New and emerging drug therapies for Alzheimer disease.” Australian prescriber vol. 47,3 (2024): 75-79. doi:10.18773/austprescr.2024.021

Westfall, Susan et al. “Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.” Cellular and molecular life sciences : CMLS vol. 74,20 (2017): 3769-3787. doi:10.1007/s00018-017-2550-9